Prevalence of bone mineral density abnormalities and related risk factors in an ambulatory HIV clinic population.
Bone mineral density (BMD) abnormalities are observed frequently among human immunodeficiency virus (HIV)-infected patients. Risk factors for reduced BMD in the setting of HIV have been previously studied, but detailed antiretroviral treatment history is often not available. A cross-sectional observational study was conducted between 2005 and 2007 among unselected HIV-infected adults attending an ambulatory urban HIV clinic. Dual-energy X-ray absorptiometry (DXA) scans of lumbar spine and femoral neck, full laboratory profile, detailed questionnaire, and antiretroviral history were obtained. Univariate and multivariate logistic regression analyses were performed to investigate factors associated with BMD below the expected range for age. Two hundred ninety patients completed the study: 80% Caucasians, 89% males, with median age of 49 yr. Low BMD as assessed by Z-score was present in 19.7% of the patients. By multivariate analysis, only lower body mass index (BMI) was an independent risk factor for low BMD. Cumulative exposure to protease inhibitors, non-nucleosides, and individual nucleoside and nucleotide analogs were not independently associated with low BMD. In conclusion, a 19.7% prevalence of abnormal BMD by DXA scan was identified in an unselected group of HIV-infected adults. Lower BMI was independently associated with low BMD. No correlation was found between abnormal BMD and cumulative exposure to any antiretroviral agents.
Guillemi
Silvia
S
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. sguillemi@cfenet.ubc.ca
Harris
Marianne
M
Bondy
Gregory P
GP
Ng
Francisco
F
Zhang
Wendy
W
Lima
Viviane D
VD
Michaels
Clara E
CE
Belzberg
Allan
A
Montaner
Julio S
JS
D015502:Absorptiometry, Photon; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000502:physiology*; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
D019380:Anti-HIV Agents; D015415:Biomarkers